Compare Sibanye Stillwater Ltd (SBSW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Sibanye Stillwater Ltd trades at $8.59 (market cap $5.66B), while Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 21.5× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays a 3.89% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SBSW | VRTX | |
|---|---|---|
Market Cap | $5.66B | $121.95B |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $529.59 |
52-Week Low | $7.27 | $366.54 |
Enterprise Value | $7.28B | $116.69B |
Dividend Yield | 3.89% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
